BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35552938)

  • 1. Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands.
    Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Willemsen S; Boere IA; Schoots IG; Piek JMJ; Hofman LN; Beltman JJ; van Driel WJ; Werner HMJ; Baalbergen A; van Haaften-de Jong AMLD; Dorman M; Haans L; Nedelcu I; Ewing-Graham PC; van Beekhuizen HJ
    Ann Surg Oncol; 2022 Aug; 29(8):4833-4843. PubMed ID: 35552938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands.
    Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Ewing-Graham PC; Schoots IG; Beltman JJ; Piek JMJ; Baalbergen A; Kooi GS; van Haaften A; van Huisseling H; Haans L; Dorman M; van Beekhuizen HJ
    BMC Cancer; 2019 Jan; 19(1):58. PubMed ID: 30642296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Study of the PlasmaJet Surgical Device Versus Conventional Cytoreductive Surgery in Patients With Advanced-Stage Ovarian Cancer.
    Nieuwenhuyzen-de Boer GM; Geraerds AJLM; van der Linden MH; van Doorn HC; Polinder S; van Beekhuizen HJ
    JCO Clin Cancer Inform; 2022 Sep; 6():e2200076. PubMed ID: 36198130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of the PlasmaJet® Device in advanced stage ovarian carcinoma: a systematic review.
    Nieuwenhuyzen-de Boer GM; van der Kooy J; van Beekhuizen HJ
    J Ovarian Res; 2019 Jul; 12(1):71. PubMed ID: 31362769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series.
    Nieuwenhuyzen-de Boer GM; van de Berg NJ; Gao XS; Ewing-Graham PC; van Beekhuizen HJ
    J Ovarian Res; 2022 Dec; 15(1):140. PubMed ID: 36581854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients.
    Nieuwenhuyzen-de Boer GM; Aamran H; van den Berg CB; Willemsen S; Piek JMJ; Reesink-Peters N; Maliepaard M; van Doorn HC; Polinder S; van Beekhuizen HJ
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].
    Liu H; Shi Y; Zhang GN; Yu J; Xu SQ; Wang DF; Fan Y; Song SQ; Zhou FZ
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):521-528. PubMed ID: 32854476
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands.
    Timmermans M; Sonke GS; Slangen BFM; Baalbergen A; Bekkers RLM; Fons G; Gerestein CG; Kruse AJ; Roes EM; Zusterzeel PLM; Van de Vijver KK; Kruitwagen RFPM; van der Aa MA
    Eur J Surg Oncol; 2019 Aug; 45(8):1425-1431. PubMed ID: 31027945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the clinical and histological appearances after treatment of advanced stage ovarian cancer with PlasmaJet® device.
    Natarajan P; Martha Schofield A; Elena Vinturache A; Ruthven S; Lane S; Duncan Macdonald R
    Eur J Obstet Gynecol Reprod Biol; 2024 May; 296():311-315. PubMed ID: 38518485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
    Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Cordeiro Vidal G; Babin G; Querleu D; Guyon F
    Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients.
    Ray MD; Deo SSV; Kumar L; Gaur MK
    Future Oncol; 2021 Sep; 17(27):3607-3614. PubMed ID: 34263662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Emerging Role of Neutral Argon Plasma (PlasmaJet) in the Treatment of Advanced Stage Ovarian Cancer: A Systematic Review.
    Prodromidou A; Pandraklakis A; Iavazzo C
    Surg Innov; 2020 Jun; 27(3):299-306. PubMed ID: 32129144
    [No Abstract]   [Full Text] [Related]  

  • 17. Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
    Algera MD; Slangen BFM; van Driel WJ; Wouters MWJM; Kruitwagen RFPM;
    Gynecol Oncol; 2023 Jul; 174():89-97. PubMed ID: 37167897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer.
    Panuccio E; Leunen K; Van Nieuwenhuysen E; Neven P; Lambrechts S; Vergote I
    Int J Gynecol Cancer; 2016 Oct; 26(8):1521-4. PubMed ID: 27488213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.